Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):1118–1121. doi: 10.1038/bjc.1993.205

Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

A Martens 1, R A Janssen 1, D T Sleijfer 1, A A Heijn 1, N H Mulder 1, T H The 1, L de Leij 1
PMCID: PMC1968458  PMID: 8494709

Abstract

Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.

Full text

PDF
1118

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  2. Fleischer B., Schrezenmeier H., Wagner H. Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. J Immunol. 1986 Mar 1;136(5):1625–1628. [PubMed] [Google Scholar]
  3. Fujimoto J., Stewart S. J., Levy R. Immunochemical analysis of the released Leu-2 (T8) molecule. J Exp Med. 1984 Jul 1;160(1):116–124. doi: 10.1084/jem.160.1.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Giblin P., Ledbetter J. A., Kavathas P. A secreted form of the human lymphocyte cell surface molecule CD8 arises from alternative splicing. Proc Natl Acad Sci U S A. 1989 Feb;86(3):998–1002. doi: 10.1073/pnas.86.3.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Griffin D. E., Ward B. J., Jauregui E., Johnson R. T., Vaisberg A. Immune activation in measles. N Engl J Med. 1989 Jun 22;320(25):1667–1672. doi: 10.1056/NEJM198906223202506. [DOI] [PubMed] [Google Scholar]
  6. Kniep E. M., Strelow I., Lohmann-Matthes M. L. The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology. 1992 Feb;75(2):299–304. [PMC free article] [PubMed] [Google Scholar]
  7. Lissoni P., Barni S., Rovelli F., Viviani S., Maestroni G. J., Conti A., Tancini G. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer. 1990 Jan;26(1):33–36. doi: 10.1016/0277-5379(90)90253-p. [DOI] [PubMed] [Google Scholar]
  8. Lotze M. T., Custer M. C., Sharrow S. O., Rubin L. A., Nelson D. L., Rosenberg S. A. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987 Apr 15;47(8):2188–2195. [PubMed] [Google Scholar]
  9. Philip T., Mercatello A., Negrier S., Philip I., Rebattu P., Kaemmerlin P., Gaspard M., Tognier E., Combaret V., Bijmann J. T. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev. 1989 Jun;16 (Suppl A):91–104. doi: 10.1016/0305-7372(89)90028-5. [DOI] [PubMed] [Google Scholar]
  10. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  11. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  12. Sleijfer D. T., Janssen R. A., Buter J., de Vries E. G., Willemse P. H., Mulder N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992 Jul;10(7):1119–1123. doi: 10.1200/JCO.1992.10.7.1119. [DOI] [PubMed] [Google Scholar]
  13. Sleijfer D. T., Janssen R. A., Willemse P. H., Martens A., de Leij L., de Vries E. G., Mulder N. H. Low-dose regimen of interleukin-2 for metastatic renal carcinoma. Lancet. 1990 Jun 23;335(8704):1522–1523. doi: 10.1016/0140-6736(90)93057-v. [DOI] [PubMed] [Google Scholar]
  14. Tomkinson B. E., Brown M. C., Ip S. H., Carrabis S., Sullivan J. L. Soluble CD8 during T cell activation. J Immunol. 1989 Apr 1;142(7):2230–2236. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES